SAN FRANCISCO, Nov. 13, 2019 /PRNewswire/ -- Akero
Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage
biotechnology company developing transformational treatments for
patients with non-alcoholic steatohepatitis (NASH) and other
serious metabolic disorders, today announced that members of the
management team will provide a business overview and update at the
Jefferies 2019 London Healthcare Conference at 8:00 a.m. GMT on
Wednesday, November 20, 2019.
A live webcast of the presentation will be available through the
investor relations section of the Company's website at
www.akerotx.com. Following the live webcast, an archived replay
will be available on the Company's website.
About Akero Therapeutics
Akero Therapeutics is a
clinical-stage biotechnology company focused on the
development and commercialization of transformative treatments for
patients with NASH and other serious metabolic diseases with high
unmet medical need. The Company's lead program AKR-001 is being
evaluated in a Phase 2a clinical trial for the treatment of
NASH. AKR-001 is an engineered human Fc-FGF21 fusion protein
designed to harness the inherent benefits of an endogenous hormone
called FGF21, with the potential to reduce liver fat, mitigate
inflammation, and reverse fibrosis in NASH patients. Akero
Therapeutics is headquartered in San
Francisco, CA. For more information, please visit
www.akerotx.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/akero-therapeutics-to-present-at-the-jefferies-2019-london-healthcare-conference-300957394.html
SOURCE Akero Therapeutics, Inc.